Océanie · Bourse & Finance · The Motley Fool Australia

CSL unveils exclusive Alentis deal to advance rare disease treatments

Publié par The Motley Fool Australia · Australie il y a 3 h

CSL unveils a major partnership for rare disease drug development, enhancing its global nephrology strategy. The post CSL unveils exclusive Alentis deal to advance rare disease…

Lire l'article complet sur The Motley Fool Australia Connectez-vous pour sauvegarder

MediaNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.fool.com.au)

CSL unveils exclusive Alentis deal to advance rare disease treatments

À lire aussi

The Trust Trap: why tighter control can hurt a growing business

Long Shortz with ClearVue Technologies: Smart glass opportunity comes into clearer view

Australia to face heat on fossil fuels at climate talks

What were they thinking?

Residents fear there is no stopping $32b hyperscale data centre

ASX 200 stocks hitting fresh 52-week highs and lows – Week 41

CSL unveils exclusive Alentis deal to advance rare disease treatments

Partager

À lire aussi

The Trust Trap: why tighter control can hurt a growing business

Long Shortz with ClearVue Technologies: Smart glass opportunity comes into clearer view

Australia to face heat on fossil fuels at climate talks

What were they thinking?

Residents fear there is no stopping $32b hyperscale data centre

ASX 200 stocks hitting fresh 52-week highs and lows – Week 41